H.C. Wainwright analyst Joseph Pantginis upgraded BerGenBio to Buy from Neutral with a NOK 30 price target. "Now is an opportune time to step off the sidelines with BerGenBio, with its clear focus and strategy in place for bemcentinib," Pantginis tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly